# US 2026/0062448 A1 · Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062448 A1
- Document ID: US20260062448A1
- Status: Published application
- Kind: A1
- Application number: 19/229,679
- Filed: 2025-06-05
- Published: 2026-03-05
- Earliest claimed: 2011-05-11
- Assignees: Apellis Pharmaceuticals, Inc.
- Applicants: Apellis Pharmaceuticals, Inc.
- Inventors: Cedric Francois; Pascal Deschatelets
- Web page: https://patentgrep.com/patent/US20260062448A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/472: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

## Claims

### Claim 1

A physiologically acceptable or pharmaceutical grade composition comprising a cell-reactive compstatin analog.

### Claim at position 2

-33. (canceled)

### Claim 34

An isolated cell or organ having a compstatin analog covalently bonded thereto.

### Claim at position 4

-53. (canceled)

### Claim 54

A long-acting compstatin analog comprising a clearance reducing moiety (CRM) that has a molecular weight of at least 20 kilodaltons (kD).

### Claim 55 (depends on 54)

The long-acting compstatin analog of claim 54 comprising a clearance-reducing moiety (CRM) having a molecular weight of between 20 kilodaltons (kD) and 100 kD.

### Claim 56 (depends on 54)

The long-acting compstatin analog of claim 54 comprising a clearance-reducing moiety having a molecular weight of at least 30 kilodaltons (kD).

### Claim 57 (depends on 54)

The long-acting compstatin analog of claim 54 comprising a clearance-reducing moiety having a molecular weight of at least 40 kilodaltons (kD).

### Claim 58 (depends on 54)

The long-acting compstatin analog of claim 54, wherein the clearance reducing moiety comprises polyethylene glycol (PEG).

### Claim 59 (depends on 54)

The long-acting compstatin analog of claim 54, wherein the clearance reducing moiety comprises a linear PEG.

### Claim at position 11

-113. (canceled)

### Claim 114 (depends on 54)

A method of reducing the sensitivity of a cell or organ to complement-dependent damage, the method comprising contacting the cell or organ with the long-acting compstatin analog of claim 54.

### Claim at position 13

-136. (canceled)
